CSIMarket
 


Moonlake Immunotherapeutics  (MLTX)
Other Ticker:  
 
 

MLTX's Net Income Growth by Quarter and Year

Moonlake Immunotherapeutics's Net Income results by quarter and year




MLTX Net Income (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December -7.89 -29.64 2.24 0.00
III Quarter September -11.62 -14.74 -2.09 0.00
II Quarter June -12.35 -17.42 -0.15 0.00
I Quarter March -12.22 -2.70 0.00 0.00
FY   -44.08 -64.50 0.00 0.00



MLTX Net Income fourth quarter 2023 Y/Y Growth Comment
Moonlake Immunotherapeutics in the fourth quarter 2023 recorded net loss of $ -7.89 millions.

According to the results reported in the fourth quarter 2023, Moonlake Immunotherapeutics achieved the best Net Income growth in Major Pharmaceutical Preparations industry. While Moonlake Immunotherapeutics' s Net Income no change of % ranks overall at the positon no. in the fourth quarter 2023.




MLTX Net Income ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Moonlake Immunotherapeutics's fourth quarter 2023 Net Income $ -7.89 millions MLTX's Income Statement
Moonlake Immunotherapeutics's fourth quarter 2022 Net Income $ -29.64 millions Quarterly MLTX's Income Statement
New: More MLTX's historic Net Income Growth >>


MLTX Net Income (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Net Income fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Net Income fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Net Income by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Moonlake Immunotherapeutics's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


MLTX's IV. Quarter Q/Q Net Income Comment
Even if Moonlake Immunotherapeutics in the IV. Quarter 2023 admitted net loss of $ -7.89 millions, management said, that this show recovery relative to the -11.62 millions in the third quarter.

Within Major Pharmaceutical Preparations industry Moonlake Immunotherapeutics achieved highest sequential Net Income growth. While Moonlake Immunotherapeutics's Net Income growth quarter on quarter, overall rank is .


Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


MLTX's IV. Quarter Q/Q Net Income Comment
Despite the fact, that Moonlake Immunotherapeutics in the IV. Quarter 2023 showed net loss of $ -7.89 millions, it should be mentioned, that current results point to recovery relative to the -11.62 millions in the third quarter.

Within Major Pharmaceutical Preparations industry Moonlake Immunotherapeutics achieved highest sequential Net Income growth. While Moonlake Immunotherapeutics's Net Income growth quarter on quarter, overall rank is .


Moonlake Immunotherapeutics's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Net Income 12 Months Ending $ -44.08 $ -65.84 $ -68.96 $ -74.02 $ -64.51
Y / Y Net Income Growth (TTM) - - - - -
Year on Year Net Income Growth Overall Ranking # # # # #
Seqeuential Net Income Change (TTM) - - - - -
Seq. Net Income Growth (TTM) Overall Ranking # # # # #




Cumulative Net Income growth Comment


Moonlake Immunotherapeutics achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Net Income growth Comment


Moonlake Immunotherapeutics achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Net Income Growth
Major Pharmaceutical Preparations Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
MLTX's Net Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for MLTX's Competitors
Net Income Growth for Moonlake Immunotherapeutics's Suppliers
Net Income Growth for MLTX's Customers

You may also want to know
MLTX's Annual Growth Rates MLTX's Profitability Ratios MLTX's Asset Turnover Ratio MLTX's Dividend Growth
MLTX's Roe MLTX's Valuation Ratios MLTX's Financial Strength Ratios MLTX's Dividend Payout Ratio
MLTX's Roa MLTX's Inventory Turnover Ratio MLTX's Growth Rates MLTX's Dividend Comparisons



Companies with similar Net Income no change for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Net Income for the quarter ending Dec 31 2023
Charles River Laboratories International inc -0.08%$ -0.081 millions
Sanuwave Health Inc -0.23%$ -0.232 millions
Regeneron Pharmaceuticals Inc -3.13%$ -3.133 millions
Haemonetics Corporation-5.17%$ -5.169 millions
Resmed Inc -7.16%$ -7.165 millions
Edwards Lifesciences Corporation-7.20%$ -7.204 millions
Star Equity Holdings Inc -9.48%$ -9.481 millions
Bristol myers Squibb Company-12.99%$ -12.988 millions
Gilead Sciences Inc -13.23%$ -13.227 millions
Utah Medical Products Inc-13.50%$ -13.499 millions
Alpha Tau Medical Ltd -13.64%$ -13.640 millions
Masimo Corp-17.13%$ -17.125 millions
Merit Medical Systems Inc-17.28%$ -17.281 millions
Fresenius Medical Care Ag-18.10%$ -18.099 millions
Qiagen N v -19.35%$ -19.354 millions
Mettler toledo International Inc -30.49%$ -30.485 millions
Avantor Inc -30.49%$ -30.487 millions
Sanofi-35.93%$ -35.926 millions
Icu Medical Inc-38.15%$ -38.151 millions
Amedisys Inc -39.71%$ -39.707 millions
Avanos Medical Inc -40.34%$ -40.341 millions
Embecta Corp -42.90%$ -42.898 millions
Pro dex Inc -43.12%$ -43.117 millions
Becton Dickinson And Company-44.79%$ -44.794 millions
Bio techne Corp-45.08%$ -45.075 millions
Harmony Biosciences Holdings inc -45.15%$ -45.150 millions
Exagen Inc -45.72%$ -45.721 millions
Amgen Inc -52.54%$ -52.537 millions
Biogen Inc -54.70%$ -54.704 millions
Taro Pharmaceutical Industries Ltd-56.33%$ -56.330 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com